Hastane öncesi trombolitik tedavi

ZOGHİ, Mehdi

Hastane öncesi trombolitik tedavi

Mehdi ZOGHİ (Ege Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, İzmir, Türkiye)

Anadolu Kardiyoloji Dergisi

2 0

Yıl: 2007 Cilt: 7 Sayı: 1 Sayfa Aralığı: 59 - 64 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Hastane öncesi trombolitik tedavi

Öz:

Akut ST segment yüksekliği olan miyokard infarktüsünde intravenöz trombolitik ajanlarla reperfüzyon tedavisi infarkt alanını sınırlandırmakta, ventrikül fonksiyonlarını korumakta ve dolayısıyla mortaliteyi azaltmaktadır. Deneysel ve klinik çalışmalar başarılı reperfüzyon zamanını, hayatta kalmanın önemli bir belirteci olarak göstermiştir. Bu yazıda çok erken (hastane öncesi) trombolizin önemi, perkütan girişimsel tedavi ile karşılaştırması ve Türkiye’deki uygulanabilirliği tartışılmaktadır. ST segment yüksekliği olan akut miyokard infarktüs hastalarında primer koroner girişimler önerilmesine rağmen hastane öncesinde intravenöz erken bolus trombolitik tedavi primer anjiyoplasti kadar iyi bir tedavi seçeneği olmaktadır. Hastane öncesi trombolitik tedavi için gerekli yasal ve teknik alt yapı tamamlanana kadar kardiyoloji merkezleri tedavi rehberleri ile kendi imkan ve tecrübelerine dayanarak en uygun reperfüzyon stratejisini uygulamak sorumluluğunda olmalıdır.

Anahtar Kelime: Acil tıp servisleri Acil tedavi Fibrinolitik ajanlar Trombolitik tedavi İnfüzyonlar, ven içi Miyokard enfarktüsü

Konular: Kalp ve Kalp Damar Sistemi

Pre-hospital thrombolytic therapy

Öz:

Reperfusion therapy with intravenous thrombolytic agents in acute ST-segment elevation myocardial infarction reduces the infarct size, preserves ventricular function, and therefore reduces mortality. Experimental and clinical studies also showed that time to successful reperfusion is a critical determinant of survival. In this paper the importance of very early (pre-hospital) thrombolysis, its comparison with percutaneous interventional therapy and the feasibility in Turkey are discussed. Although primary coronary interventions are preferred in patients with ST-segment elevation myocardial infarction intravenous, early bolus thrombolysis in the pre-hospital stage provides a therapeutic option as good as primary angioplasty. Until necessary policy and technical substructure are completed cardiology centers should apply the most suitable reperfusion strategy according with the guidelines, feasibilities and their experience.

Anahtar Kelime: Thrombolytic Therapy Infusions, Intravenous Myocardial Infarction Emergency Medical Services Emergency Treatment Fibrinolytic Agents

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Tillet WS. Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exptl Med 1933; 58: 485.
2. Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998; 352: 1771-4.
3. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-60.
4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. Circulation 2006; 113 : 166-286.
5. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000; 83: 361-6.
6. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-57.
7. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med 2004; 1: 96-102.
8. Schaper W, Binz K, Sass S, Winkler B. Influence of collateral blood flow and of variations in MVO2 on tissue-ATP content in ischemic and infarcted myocardium. J Mol Cell Cardiol 1987; 19: 19-37.
9. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave front phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-94.
10. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311-22.
11. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. The International Study Group. Lancet 1990; 336: 71-5.
12. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-70.
13. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-82.
14. Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation 1996; 94: 1233-8.
15. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
16. Antman EM, Anbe DT,Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: E1-E211.
17. Lange RA, Hillis LD. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction. N Engl J Med 1996; 335: 1311-7.
18. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
19. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21: 823-31.
20. Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thayssen P, et al. DANAMI-2 Investigators. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J 2003; 146: 234-41.
21. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003; 24: 94-104.
22. Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logemann TL, Niemela M, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39: 1713–9.
23. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, Steg G, McFadden EP, Dubien PY, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-9.
24. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-6.
25. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283: 2941–7.
26. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 42: 824–6.
27. Juliard JM, Feldman LJ, Golmard JL, Himbert D, Benamer H, Haghighat T, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol 2003; 91: 1401–5.
28. Giugliano RP, Braunwald E. The TIMI Study Group. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation 2003; 108: 2828-30.
29. Gibson CM. Time is myocardium and time is outcomes. Circulation 2001; 104: 2632-4.
30. Chang WC, Midodzi WK, Westerhout CM, Boersma E, Cooper J, Barnathan ES, et al. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health 2005; 59: 427-33.
31. Schomig A, Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen H, Nekolla S, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation. 2003; 108: 1084–8.
32. Williams DO. Treatment delayed is treatment denied. Circulation 2004; 109: 1806-8.
33. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Circulation 1994; 90: 2658-65.
34. Boersma E. Pre-hospital fibrinolytic therapy. In: Verheugt F, editor. Fibrinolytic Therapy in Clinical Practice. London, New York: Martin Dunitz, Taylor & Francis group; 2004. p.111-30.
35. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000; 283:2686-92.
36. Banerjee S, Rhoden WE. Fast-tracking of myocardial infarction by paramedics. J R Coll Physicians Lond 1998; 32:36-8.
37. Weaver CS, Avery SJ, Brizendine EJ, McGrath RB. Impact of emergency medicine faculty on door to thrombolytic time. J Emerg Med 2004; 26: 279-83.
38. Weaver WD, Cerqueira M, Hallstrom AP, Ross AM, Woodlief LH, Califf RM, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-6.
39. Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23: 1–5.
40. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761-7.
41. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: the era of reperfusion: section 1: acute coronary syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 22; 102 (8 Suppl): I172-203.
42. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee, 60 Minutes to Treatment Working Group. Ann Emerg Med 1994;23: 311-29.
43. Lamfers EJ, Schut A, Hertzberger DP, Hooghoudt TE, Stolwijk PW, Boersma E, et al. Prehospital versus hospital fibrinolytic therapy using automated versus cardiologist electrocardiographic diagnosis of myocardial infarction: abortion of myocardial infarction and unjustified fibrinolytic therapy. Am Heart J 2004; 147: 509-15.
44. Arntz HR. Prehospital thrombolysis in acute myocardial infarction. Thromb Res 2001; 103 (Suppl 1): S91-6.
45. TÜMAR çalışmacıları. Türkiye Akut Miyokard İnfarktüsü Araştırması. İstanbul: Bristol-Mayer Squibb Inc. Şirketi yayınları 2002.
46. Danchin N, Vaur L, Genes N, Etienne S, Angioi M, Ferrieres J, Cambou JP. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey. Circulation 1999; 99: 2639-44.
47. Arat N, Gulel N, Sabah I. Has the mortality rate from acute myocardial infarction fallen substantially in recent years? Single center data on elderly patient population. Anadolu Kardiyol Derg 2005; 5: 101-7.
48. Aslan BU, Karcioglu O, Aslan O, Ayrik C, Kulac E, Guneri S. Does the short-term mortality differ between men and women with first acute myocardial infarction? Anadolu Kardiyol Derg 2002; 2: 284-90.
49. Norgaz T, Hobikoğlu G, Aksu H, Esen A, Gül M, Özer HO, et al. ST yükselmeli akut miyokard infarktüsünde hastane öncesi gecikme süresi ile klinik, demografik ve sosyoekonomik etkenlerin ilişkisi: Hasta eğitiminin önemi. Türk Kardiyol Dern Arş 2005; 33: 392-7.

APA	ZOGHİ M (2007). Hastane öncesi trombolitik tedavi. , 59 - 64.
Chicago	ZOGHİ Mehdi Hastane öncesi trombolitik tedavi. (2007): 59 - 64.
MLA	ZOGHİ Mehdi Hastane öncesi trombolitik tedavi. , 2007, ss.59 - 64.
AMA	ZOGHİ M Hastane öncesi trombolitik tedavi. . 2007; 59 - 64.
Vancouver	ZOGHİ M Hastane öncesi trombolitik tedavi. . 2007; 59 - 64.
IEEE	ZOGHİ M "Hastane öncesi trombolitik tedavi." , ss.59 - 64, 2007.
ISNAD	ZOGHİ, Mehdi. "Hastane öncesi trombolitik tedavi". (2007), 59-64.

APA	ZOGHİ M (2007). Hastane öncesi trombolitik tedavi. Anadolu Kardiyoloji Dergisi, 7(1), 59 - 64.
Chicago	ZOGHİ Mehdi Hastane öncesi trombolitik tedavi. Anadolu Kardiyoloji Dergisi 7, no.1 (2007): 59 - 64.
MLA	ZOGHİ Mehdi Hastane öncesi trombolitik tedavi. Anadolu Kardiyoloji Dergisi, vol.7, no.1, 2007, ss.59 - 64.
AMA	ZOGHİ M Hastane öncesi trombolitik tedavi. Anadolu Kardiyoloji Dergisi. 2007; 7(1): 59 - 64.
Vancouver	ZOGHİ M Hastane öncesi trombolitik tedavi. Anadolu Kardiyoloji Dergisi. 2007; 7(1): 59 - 64.
IEEE	ZOGHİ M "Hastane öncesi trombolitik tedavi." Anadolu Kardiyoloji Dergisi, 7, ss.59 - 64, 2007.
ISNAD	ZOGHİ, Mehdi. "Hastane öncesi trombolitik tedavi". Anadolu Kardiyoloji Dergisi 7/1 (2007), 59-64.